

Gemini Stock Analysis Report

Based on the detailed analysis of the attached report for **CIPLA.NS**, here is the positional trading assessment.

Note on Data Context: The report data is dated **January 3, 2026**. I will conduct this analysis treating this date as "current" and the price of **INR 1511.60** as the live price.

Step 1: Audit the Data

• Data Present:

- **Price Action:** 3-Year Daily Chart, daily close prices.
- **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend.
- **Momentum Indicators:** RSI (14), MACD (12, 26, 9).
- **Volatility:** Bollinger Bands (width and position), ATR, Volatility Squeeze analysis.
- **Relative Strength:** RS Score, RS Ratio vs. Nifty Pharma (^CNXPHARMA).
- **Fundamentals:** Revenue/Net Income growth trends, Valuation scores, Analyst targets.

• Data Missing:

- **Volume Profile:** While volume bars are present, a Volume Profile (Price by Volume) to identify specific supply/demand shelves is missing.
 - **Weekly/Monthly Candles:** Explicit weekly charts for higher timeframe trend confirmation are not shown (though can be inferred from the 3-year daily view).
- **Confidence Level: High.** The report provides a comprehensive suite of technical, fundamental, and relative strength metrics sufficient for a positional trade decision.
-

Step 2: Analyze the Setup

1. Price Structure & Trend (The "Coil"): * **Status: Consolidation / Compression.** * The stock is currently trading at **INR 1511.60**, sandwiched tightly between the EMA 20 (INR 1505) and the EMA 200 (INR 1516). * The EMA 20, 50, and 200 are converging within a tiny range (approx. 10 points). This indicates a significant contraction in volatility and often precedes an explosive move. * The report explicitly identifies a **Volatility Squeeze** (Page 14/15) with signals active from late Dec 2025 to Jan 2026. This is the most critical setup feature.

2. Momentum & Oscillators: * **MACD:** **Bullish.** The MACD line has crossed above the Signal line (Page 12), and the histogram is expanding positively. This suggests upward momentum is building despite the flat price action. * **RSI:** **Neutral (51.53).** It is neither overbought nor oversold, providing ample room for a move in either direction. * **Supertrend:** **Bearish.** The current trend status is "Sell" with a resistance level at **INR 1539.46**. This is the key lid on the stock right now.

3. Relative Strength: * **Weakness:** The stock has an RS Score of **48.6/100** and is lagging the Pharma sector (Page 4). This is a concern; we prefer to buy leaders. However, if the sector rotates, CIPLA could play catch-up.

4. Fundamentals: * Analyst consensus targets (Page 19) suggest a price of **INR 1673** (approx. +10.7%), aligning with the technical upside.

Gemini Stock Analysis Report

Step 3: Formulate the Recommendation

Decision: NO (Do not enter at current market price of 1511.60).

Rationale: While the "Squeeze" setup is attractive, the stock is currently trading *below* its 200-day EMA (INR 1516) and below the SuperTrend resistance (INR 1539). Entering now is "guessing" the direction of the breakout. Given the Relative Strength weakness, there is a risk the squeeze could fire to the downside. We require price confirmation to validate the bullish momentum suggested by the MACD.

Conditional Plan (Buy Stop Strategy): We will set a conditional order to enter only if strength is confirmed by reclaiming key resistance levels.

- **Condition to Buy: A Daily Close above INR 1540.**
 - *Why:* This clears the EMA 200 (1516) and flips the SuperTrend (1539) from **Bearish** to **Bullish**.
- **Entry Price: INR 1540 - INR 1545** (Limit order upon confirmation).
- **Stop Loss: INR 1480** (Hard closing basis).
 - *Why:* This is just below the Lower Bollinger Band (INR 1485) and the recent consolidation lows. If it breaches this, the squeeze has fired downwards.
- **Take Profit: INR 1670.**
 - *Why:* This targets the recent swing highs (Oct 2025) and matches the analyst consensus target provided in the report.

Trade Statistics (Hypothetical): * **Risk:** ~INR 60 per share (approx. 4%). * **Reward:** ~INR 130 per share (approx. 8.5%). * **Risk/Reward Ratio:** ~1:2.1 (Acceptable for intermediate swing).

News & Analyst Targets

Stock Research Report: CIPLA Date: January 3, 2026

Here is the latest research and information regarding **Cipla Ltd.** for the current week.

1) Latest News for CIPLA (Week ending Jan 3, 2026)

- **Exclusive Partnership with Pfizer:** The most significant recent development is Cipla's exclusive 5-year supply and marketing agreement with **Pfizer India**.
 - **Details:** Cipla has secured sole rights to market and distribute four key Pfizer brands in India: **Corex Dx & Corex LS** (cough syrups), **DoloneX** (pain management), **Neksium** (proton pump inhibitor), and **Dalacin C** (antibiotic).
 - **Impact:** Pfizer will continue to manufacture these drugs, while Cipla will leverage its extensive distribution network to boost their reach. This is expected to strengthen Cipla's domestic portfolio significantly.
- **Senior Management Change:** The company announced the superannuation of **Dr. Raju Mistry**, Global Chief People Officer and Senior Management Personnel, effective **December 31, 2025**. A successor will be announced in due course.
- **Upcoming Board Meeting:** Cipla has scheduled a Board of Directors meeting for **Friday, January 23, 2026**, to consider and approve the unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26).

Gemini Stock Analysis Report

2) Brokerage Upgrades/Downgrades

- **Motilal Oswal:** Recently set a target of **INR 1,500**, maintaining a neutral/cautious stance given the stock was trading near INR 1,505 levels at the time of the note (Dec 29, 2025).
- **PhillipCapital:** Maintained a **Hold** rating with a target of **INR 1,420** (report dated Dec 24, 2025), citing valuation concerns despite steady growth.
- **Consensus View:** The broader analyst community remains divided. While some global brokerages like Nomura and HSBC have "Buy" ratings from late 2025, domestic sentiment is currently mixed with several "Hold" or "Neutral" calls due to the recent stock run-up and valuation.

3) Other News Impacting CIPLA

- **Stock Performance:** On Friday, January 2, 2026, Cipla's stock closed around **INR 1,511**, up approximately **0.7%**, showing resilience amidst a mixed market.
- **Regulatory Environment:** The US FDA landscape remains a key monitorable. While no new adverse observations were reported specifically in the first days of 2026, the company continues remediation efforts at its Pithampur and Goa facilities following observations in 2025.
- **Sector Trends:** The Nifty Pharma index has shown mixed signals. The Pfizer deal highlights a growing trend of "big pharma" partnerships (MNCs partnering with Indian majors for distribution) to penetrate Tier-2 and Tier-3 cities.

4) Analyst Targets (Latest Available)

The following table summarizes the most recent specific price targets from major brokerage houses.

Brokerage Firm	Rating / Action	Target Price (INR)	Date of Report
Nomura / Instinet	Buy	1,770	Nov 03, 2025
HSBC	Buy	1,720	Oct 30, 2025
CLSA	Hold	1,670	Oct 30, 2025
Motilal Oswal	Neutral	1,500	Dec 29, 2025
Goldman Sachs	Sell	1,425	Oct 30, 2025
PhillipCapital	Hold	1,420	Dec 24, 2025
Consensus Mean	Outperform	~1,673	Jan 03, 2026

Note: Targets are based on the latest available reports leading into January 2026. "Consensus Mean" represents the average of all active analyst coverage.

Stock Detailed Analysis Report

CIPLA.NS

Current Price: ₹1511.60

Generated: 2026-01-03 12:44

CIPLA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	6.68%	7.88%
Net Income	Yes	No	27.93%	27.96%
ROE	Yes	No	9.52%	11.86%
EPS	Yes	No	27.89%	27.91%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.63%	0.87%
Net Income	Yes	6.20%	3.79%
ROE	No	-14.71%	-14.71%
EPS	Yes	20.58%	15.61%

CIPLA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Neutral
RS Score:	48.6/100
:	

== RS RATIOS ==:

1M RS:	0.999 [Neutral]
3M RS:	0.940 [Neutral]
6M RS:	0.966 [Neutral]
1Y RS:	0.985 [Neutral]
:	




== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::

✓ Emerging RS:	1M (0.999) > 3M (0.940)
✓ Medium-term Lagging:	6M=0.966, 1Y=0.985 (≤ 1.0)
✗ Performance Improving:	Not improving


Relative Strength Analysis: CIPLA.NS vs ^CNXPHARMA
Classification: Neutral
Price Performance Comparison (Normalized)



CIPLA.NS - EMA Crossover Summary

EMA 20:	1505.61
EMA 50:	1515.35
EMA 200:	1516.51
Trend Status:	Strong Downtrend


CIPLA.NS EMA Crossover Analysis



CIPLA.NS - Bollinger Bands Summary

Current Price:	1511.60
Upper Band:	1520.06
Middle Band (SMA 20):	1502.59
Lower Band:	1485.12
%B:	0.7579
Band Width:	0.0233
Status:	Upper Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-10-23 00:00:00

CIPLA.NS Bollinger Bands (20, 2) Analysis




CIPLA.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 1539.46

Signal Identified On: 2025-10-28


Supertrend Analysis for CIPLA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




CIPLA.NS - MACD Summary

MACD Line:	-3.74
Signal Line:	-5.32
Histogram:	1.57
Trend:	Bullish
Momentum:	Strengthening
Signal:	None

CIPLA.NS Price






CIPLA.NS MACD (12, 26, 9)



CIPLA.NS - Volatility Squeeze Summary

BB Width:	0.0233
ATR:	17.3357
Total Signals:	36
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-29 00:00:00 (Price: 149.00)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-30 00:00:00 (Price: 149.00)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00 (Price: 150.00)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00 (Price: 150.00)
Signal 5:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00 (Price: 150.00)




CIPLA.NS - Volatility Squeeze Analysis



CIPLA.NS - RSI-Volume Summary

Current RSI:	51.53
Current Volume:	964611
Volume MA 20:	949079
Bullish Divergences:	0
Bearish Divergences:	5
Bearish Div 1:	Date: 2024-10-09 00:00:00, Price: 1680.50
Bearish Div 2:	Date: 2025-08-25 00:00:00, Price: 1601.20

CIPLA.NS RSI-Volume Divergence Analysis



Trendlyne Snapshot - CIPLA_main

Markets STARFOLIO Alerts F&O MF Reports Screeners Subscribe Superstars Portfolio Watchlist Insider Trades Results Data Downloader More Search Stock, IPO, MF India A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / CIPLA LTD.

Cipla Ltd. [①](#)
NSE: CIPLA | BSE: 500087
Cipla Live Share Price Today, Share Analysis and Chart

■ ■ ■ Mid-range Performer [①](#) [②](#) In 10 Starfolio Baskets

1511.60 10.70 (0.71%) **1.0M** NSE+BSE Volume
NSE 02 Jan, 2026 3:31 PM (IST)

ABOUT Founded in 1935 as Chemical Industrial & Pharmaceutical Laboratories, it was renamed Cipla in 1984. Cipla is in the business of manufacturing, developing and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredien... [Read More](#)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Durability score [①](#) **75.0 /100** Valuation Score [①](#) **41.7 /100** Momentum Score [①](#) **49.1 /100** Analyst Price Target [①](#) [②](#) **1,673** 1Yr Price target upside is 11%
High Financial Strength Mid Valuation Technically Neutral
Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potent... View Similar [③](#) Embed DVM [④](#)

FORECASTER DVM Key Metrics Price Chart Forecaster Financials Technicals Shareholding Preset Metrics Documents Corporate actions Company Profile X

Check Before You Buy [VIEW FULL CHECKLIST](#)
High rank 17 Positive * 6 Negative 73.9% Pass in checklist
0 45 55 100

PE Valuation Check
Right Now [①](#) Undervalued 36.2% 1 Year Forward [①](#) Undervalued 21.6%
IN SIGHT Cipla is undervalued at both current PE and future earnings estimates.

Cipla Key Metrics

ROE Ann. % [①](#) Above industry Median **16.9** Broker Average Target [①](#) 12.29% upside **1,697.44** Market Capitalization [①](#) High in Industry **122,102.8** Price to Book [①](#) Above industry Median

Trendlyne Snapshot - CIPLA_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [Search Stock, IPO, MF](#) [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [CIPLA LTD.](#)

Cipla Ltd. ⓘ
NSE: CIPLA | BSE: 500067
Mid-range Performer ⓘ In 10 Starfolio Baskets

Download real time STOCK REPORT

1511.60 10.70 (0.71%) **1.0M** NSE+BSE Volume
NSE 02 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes TRADE STOCK

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

Cipla - CIPLA - stock price prediction, stock forecast, target price, analyst ratings from 36 analysts

Cipla has a share price target of Rs 1673, revenue growth forecast of 6.3%, and profit growth estimate of -7.3% for FY26, based on top 36 analyst calls.

Cipla FORECASTER - Analyst Estimates ⓘ

[FORECASTER DASHBOARD →](#)
